FIELD: biotechnology.
SUBSTANCE: antibodies are proposed that specifically bind to Notch1. Also, nucleic acids that encode said antibodies, vectors, host cells and methods for producing antibodies are proposed. In addition, the invention relates to a pharmaceutical composition comprising these antibodies and methods for treating disorders, mediated from Notch1, by said antibodies or a pharmaceutical composition containing them.
EFFECT: invention can be used in therapy against Notch1 for the treatment of cancer.
27 cl, 30 dwg, 45 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST NOTCH2 AND METHODS FOR APPLICATION THEREOF | 2009 |
|
RU2580029C2 |
| ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) | 2003 |
|
RU2303461C9 |
| NRR Notch1 ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2008 |
|
RU2476443C2 |
| HUMANISED ANTIBODY AND ANTIGENBINDING FRAGMENT (Fab), WHICH BINDS WITH HUMAN INTERFERON-γ, DNA FRAGMENTS CODING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT, CELL, TRANSFORMED BY DNA FRAGMENT, AND METHOD OF OBTAINING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT | 2013 |
|
RU2539752C2 |
| HUMANISED 5D3HU ANTIBODY BINDING TO THE PRAME TUMOUR ANTIGEN, DNA FRAGMENTS ENCODING SAID ANTIBODY, AND ANTIGEN-BINDING FRAGMENT OF THE ANTIBODY | 2020 |
|
RU2761876C1 |
| HUMANIZED ANTIBODY 6H8HU, BINDING TO TUMOUR ANTIGEN PRAME, DNA FRAGMENTS CODING SAID ANTIBODY AND ANTIGEN-BINDING ANTIBODY FRAGMENT | 2020 |
|
RU2768737C1 |
| HUMANISED MONOCLONAL ANTIBODY SPECIFIC TO SYNDECAN-1 | 2013 |
|
RU2551235C2 |
| ANTIBODY AGAINST CD147 | 2018 |
|
RU2785293C2 |
| HUMANIZED IMMUNE BODIES IDENTIFYING ALPHA-SINUCLEIN | 2012 |
|
RU2575629C2 |
| AGONIST NOTCH3 ANTIBODIES AND APPLICATION THEREOF FOR TREATING NOTCH3-ASSOCIATED DISEASES | 2007 |
|
RU2461569C2 |
